ArticleInvestigative ophthalmology & visual science2026
Tannic Acid Achieves Rapid Scar-Free Corneal Healing by Chelating Excess Copper to Suppress Aberrant LOX-Mediated Fibrosis.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Corneal scarring and fibrosis following injury remain the leading causes of visual impairment worldwide. This study aimed to evaluate the therapeutic effects of tannic acid (TA), a natural polyphenolic compound with antioxidant, anti-inflammatory, and metal-chelating properties, and to elucidate its underlying molecular mechanisms in corneal wound healing. Methods: In vitro (human corneal epithelial and stromal cells) and in vivo (rabbit anterior lamellar keratectomy) models were established to evaluate TA's efficacy. Epithelial migration was assessed by scratch and Transwell assays, whereas TGF-β-induced models evaluated anti-fibrotic activity. Histopathology was examined by hematoxylin and eosin, Masson's trichrome staining, and α-SMA immunohistochemistry. Transcriptomic sequencing, Western blot, and RT-qPCR analyzed gene and protein expression. Copper ion concentrations were measured by inductively coupled plasma mass spectrometry (ICP-MS), and lysyl oxidase (LOX) enzymatic activity was determined using fluorometric activity assay kits. Results: Within biocompatible concentrations, TA dose-dependently promoted epithelial cell migration and suppressed stromal fibrosis in vitro. In vivo, TA treatment achieved rapid scar-free healing, outperforming rhEGF treatment. Mechanistic investigations revealed that TA exerts anti-fibrotic effects by downregulating LOX family gene expression and modulating collagen fibril assembly pathways. Protein and mRNA analyses confirmed that TA suppresses LOX expression and activity through chelation of excess copper ions, with functional validation via exogenous copper supplementation further supporting this mechanism. Conclusions: These findings demonstrate that TA chelates excess copper ions accumulated in injured corneas, thereby mediating LOX inhibition and reducing fibrosis, representing an important mechanistic complement to TA's established antioxidant and anti-inflammatory properties.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.